logo
logo
BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc.

NASDAQ•BCRX
CEO: Mr. Jon P. Stonehouse
セクター: Healthcare
業種: Biotechnology
上場日: 1994-03-04
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
連絡先情報
4505 Emperor Boulevard, Suite 200, Durham, NC, 27703, United States
919-859-1302
www.biocryst.com
時価総額
$1.46B
PER (TTM)
-166.4
19.5
配当利回り
--
52週高値
$11.31
52週安値
$6.00
52週レンジ
18%
順位58Top 85.6%
2.3
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$159.40M+36.14%
直近4四半期の推移

EPS

$0.06-187.71%
直近4四半期の推移

フリーCF

$39.77M+385.79%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Nine Month Revenue Soars 46.7% Total revenues reached $468.3M for nine months ended September 30, 2025, up $149.1M from prior period.
Nine Month Net Income Rebounds Swung to $18.0M net income for nine months 2025, compared to $62.1M loss in 2024.
ORLADEYO Drives Revenue Increase ORLADEYO net revenue increased $136.7M for nine months 2025, driven by strong patient demand and pricing.
European Sale Funds Debt Payoff Proceeds from European ORLADEYO sale used to fully pay off $198.7M Pharmakon Loan principal October 2025.

リスク要因

Generic Competition Threat Looms Annora filed ANDA challenging ORLADEYO patents; litigation is early stage, outcome uncertain for future exclusivity.
Future Capital Needs Uncertain Sustained profitability not yet achieved; future operations depend on securing additional capital if needed.
Reliance on Single Distributor Relies on single specialty pharmacy for US ORLADEYO distribution; disruption could severely impact commercial revenue.
Astria Merger Integration Risks Combining Astria business may be difficult, costly, or time-consuming, potentially delaying realization of anticipated benefits.

見通し

BCX17725 Fast Track Status BCX17725 received FDA Fast Track designation; initial Phase 1 trial data expected by end of Q1 2026.
Seeking Avoralstat Partner Expect initial Avoralstat data by year-end 2025; planning to seek strategic partner for development beyond Phase 1.
New Credit Facility Secured Entered $550.0M senior secured credit facility commitment with Blackstone, contingent upon Astria Merger closing.
Pediatric ORLADEYO Submission PDUFA goal date set for December 12, 2025, for new drug application of ORLADEYO granules in children.

同業比較

売上高 (TTM)

BioCryst Pharmaceuticals, Inc.BCRX
$599.82M
+45.4%
Ardelyx, Inc.ARDX
$398.23M
+58.1%
Xeris Biopharma Holdings, Inc.XERS
$266.14M
+42.0%

粗利益率 (最新四半期)

Nanobiotix S.A.NBTX
100.0%
+0.0pp
Zymeworks Inc.ZYME
100.0%
+0.0pp
Atai Life Sciences N.V.ATAI
100.0%
+0.0pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
WVE$2.30B-17.3-75.6%8.2%
SYRE$2.17B-18.1-31.2%0.0%
STOK$1.78B44.913.3%0.8%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
6.6%
安定成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
50%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年2月23日
|
EPS:$0.07
|
売上高:$151.32M
財務レポート
財務データ
ニュース
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月4日|
    売上高: $159.40M+36.1%
    |
    EPS: $0.06-187.7%
    予想を上回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月5日|
    売上高: $163.35M+49.4%
    |
    EPS: $0.02-133.3%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月6日|
    売上高: $145.53M+56.9%
    |
    EPS: $0.00+0.0%
    不明

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月25日|
    売上高: $450.71M+36.0%
    |
    EPS: $-0.43+63.6%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月5日|
    売上高: $117.09M+35.0%
    |
    EPS: $-0.07-63.2%
    予想を上回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月6日|
    売上高: $109.33M+32.5%
    |
    EPS: $-0.06-85.0%
    予想を上回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月7日|
    売上高: $92.76M+34.9%
    |
    EPS: $-0.17-39.3%
    予想を上回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月27日|
    売上高: $331.41M+22.4%
    |
    EPS: $-1.18+11.3%
    予想を下回る